These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9231302)

  • 1. Risperidone in young children with pervasive developmental disorders and other developmental disabilities.
    Demb HB
    J Child Adolesc Psychopharmacol; 1996; 6(1):79-80. PubMed ID: 9231302
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: a chart review study.
    Adler BA; Wink LK; Early M; Shaffer R; Minshawi N; McDougle CJ; Erickson CA
    Autism; 2015 Jan; 19(1):102-6. PubMed ID: 24571823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study.
    Troost PW; Althaus M; Lahuis BE; Buitelaar JK; Minderaa RB; Hoekstra PJ
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):561-73. PubMed ID: 17069545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
    Shea S; Turgay A; Carroll A; Schulz M; Orlik H; Smith I; Dunbar F
    Pediatrics; 2004 Nov; 114(5):e634-41. PubMed ID: 15492353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risperidone in a very young child with PDD.
    Bober D; Sabzwari U; Star JE
    J Am Acad Child Adolesc Psychiatry; 2005 Aug; 44(8):725-6. PubMed ID: 16034272
    [No Abstract]   [Full Text] [Related]  

  • 6. The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder--a systematic review.
    Deb S; Farmah BK; Arshad E; Deb T; Roy M; Unwin GL
    Res Dev Disabil; 2014 Mar; 35(3):711-25. PubMed ID: 24405794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy of irritability in pervasive developmental disorders.
    Stigler KA; McDougle CJ
    Child Adolesc Psychiatr Clin N Am; 2008 Oct; 17(4):739-52, vii-viii. PubMed ID: 18775367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of risperidone in children with autism spectrum disorder.
    Chavez B; Chavez-Brown M; Rey JA
    Ann Pharmacother; 2006 May; 40(5):909-16. PubMed ID: 16684811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The autistic-spectrum disorders.
    Rapin I
    N Engl J Med; 2002 Aug; 347(5):302-3. PubMed ID: 12151466
    [No Abstract]   [Full Text] [Related]  

  • 10. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months.
    Research Units on Pediatric Psychopharmacology Autism Network
    Am J Psychiatry; 2005 Jul; 162(7):1361-9. PubMed ID: 15994720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities.
    Valicenti-McDermott MR; Demb H
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):549-60. PubMed ID: 17069544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risperidone in the treatment of pervasive developmental disorder.
    Purdon SE; Lit W; Labelle A; Jones BD
    Can J Psychiatry; 1994 Sep; 39(7):400-5. PubMed ID: 7527293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Open trial of risperidone in 24 young children with pervasive developmental disorders.
    Masi G; Cosenza A; Mucci M; Brovedani P
    J Am Acad Child Adolesc Psychiatry; 2001 Oct; 40(10):1206-14. PubMed ID: 11589534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders.
    Posey DJ; Guenin KD; Kohn AE; Swiezy NB; McDougle CJ
    J Child Adolesc Psychopharmacol; 2001; 11(3):267-77. PubMed ID: 11642476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders.
    Hellings JA; Zarcone JR; Valdovinos MG; Reese RM; Gaughan E; Schroeder SR
    J Child Adolesc Psychopharmacol; 2005 Dec; 15(6):885-92. PubMed ID: 16379508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of risperidone in developmentally disabled children.
    Kastner TA
    Pediatrics; 2005 May; 115(5):1447-8; author reply 1448. PubMed ID: 15867075
    [No Abstract]   [Full Text] [Related]  

  • 17. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism.
    Hellings JA; Zarcone JR; Crandall K; Wallace D; Schroeder SR
    J Child Adolesc Psychopharmacol; 2001; 11(3):229-38. PubMed ID: 11642473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study.
    Capone GT; Goyal P; Grados M; Smith B; Kammann H
    J Dev Behav Pediatr; 2008 Apr; 29(2):106-16. PubMed ID: 18349709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic treatment of autism and related disorders.
    Erickson CA; Posey DJ; Stigler KA; McDougle CJ
    Pediatr Ann; 2007 Sep; 36(9):575-85. PubMed ID: 17910205
    [No Abstract]   [Full Text] [Related]  

  • 20. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study.
    McDougle CJ; Holmes JP; Bronson MR; Anderson GM; Volkmar FR; Price LH; Cohen DJ
    J Am Acad Child Adolesc Psychiatry; 1997 May; 36(5):685-93. PubMed ID: 9136504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.